US5858980A
(en)
*
|
1990-03-30 |
1999-01-12 |
Autoimmune, Inc. |
Peptide fragments of myelin basic protein
|
US7090982B2
(en)
|
1991-10-22 |
2006-08-15 |
The Governors Of The University Of Alberta |
Methods of predicting therapeutic efficacy of treatment of a multiple sclerosis patient
|
US6252040B1
(en)
|
1991-10-22 |
2001-06-26 |
The Governors Of The University Of Alberta |
Peptide specificity of anti-myelin basic protein and the administration of myelin basic protein peptides to multiple sclerosis patients
|
IL113812A
(en)
|
1994-05-24 |
2000-06-29 |
Yeda Res & Dev |
Copolymer-1 pharmaceutical compositions containing it and its use
|
US5858964A
(en)
*
|
1995-04-14 |
1999-01-12 |
Yeda Research And Development Co. Ltd. |
Pharmaceutical compositions comprising synthetic peptide copolymer for prevention of GVHD
|
IL119989A0
(en)
*
|
1997-01-10 |
1997-04-15 |
Yeda Res & Dev |
Pharmaceutical compositions for oral treatment of multiple sclerosis
|
CA2320044A1
(en)
*
|
1998-02-13 |
1999-08-19 |
Ruth Maron |
Treatment of multiple sclerosis using cop-1 and th2-enhancing cytokines
|
IL141021A0
(en)
|
1998-07-23 |
2002-02-10 |
Yeda Res & Dev |
Treatment of autoimmune conditions with copolymer 1 and related copolymers
|
ES2527760T3
(es)
*
|
1998-07-23 |
2015-01-29 |
Yeda Research And Development Co., Ltd. |
Tratamiento de enfermedad de Crohn con copolímero 1 y polipéptidos
|
WO2000005249A2
(en)
|
1998-07-23 |
2000-02-03 |
The President And Fellows Of Harvard College |
Synthetic peptides and methods of use for autoimmune disease therapies
|
US6800287B2
(en)
*
|
1998-09-25 |
2004-10-05 |
Yeda Research And Development Co., Ltd. |
Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use
|
US6514938B1
(en)
|
1998-09-25 |
2003-02-04 |
Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science |
Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use
|
PT1115743E
(pt)
|
1998-09-25 |
2009-07-07 |
Yeda Res & Dev |
Polipeptídeos relacionados com copolímeros 1 para uso como marcadores de peso molecular e para uso terapêutico
|
WO2000020010A1
(en)
*
|
1998-10-02 |
2000-04-13 |
Yeda Research And Development Co., Ltd. |
Alternate day administration of copolymer 1 for treating autoimmune diseases
|
US7083777B1
(en)
|
1999-04-02 |
2006-08-01 |
The Brigham And Women's Hospital, Inc. |
Immunomodulating polymers
|
KR100822695B1
(ko)
*
|
2000-01-20 |
2008-04-17 |
예다 리서치 앤드 디벨럽먼트 캄파니 리미티드 |
코폴리머 1 및 관련된 펩티드들 및 폴리펩티드 및 이들로처치된 티세포들의 신경보호 요법을 위한 사용
|
JP2003522799A
(ja)
*
|
2000-02-18 |
2003-07-29 |
イエダ・リサーチ・アンド・ディベロップメント・カンパニー・リミテッド・アット・ザ・ウェイズマン・インスティテュート・オブ・サイエンス |
コポリマー1の経口、経鼻および経肺投与製剤
|
ZA200206457B
(en)
*
|
2000-02-18 |
2003-08-13 |
Yeda Res & Dev |
Oral, nasal and pulmonary dosage formulations of copolymer 1.
|
WO2001093828A1
(en)
*
|
2000-06-05 |
2001-12-13 |
Teva Pharmaceuticals Industries, Ltd. |
The use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders
|
US20020077278A1
(en)
*
|
2000-06-05 |
2002-06-20 |
Yong V. Wee |
Use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders
|
US20020037848A1
(en)
*
|
2000-06-07 |
2002-03-28 |
Michal Eisenbach-Schwartz |
Use of copolymer 1 and related peptides and polypeptides and T cells treated therewith for neuroprotective therapy
|
WO2002076503A1
(en)
*
|
2000-06-20 |
2002-10-03 |
Mayo Foundation For Medical Education And Research |
Treatment of central nervous system diseases by antibodies against glatiramer acetate
|
WO2001097785A2
(en)
*
|
2000-06-20 |
2001-12-27 |
Caprion Pharmaceuticals Inc. |
Basic copolymers for the treatment of prion-related-disease
|
IL137460A0
(en)
|
2000-07-24 |
2001-07-24 |
Yeda Res & Dev |
Identifying antigen clusters for monitoring a global state of an immune system
|
US20040037828A1
(en)
|
2002-07-09 |
2004-02-26 |
Bar-Ilan University |
Methods and pharmaceutical compositions for healing wounds
|
SV2003000753A
(es)
|
2000-12-05 |
2003-06-16 |
Brigham & Womens Hospital |
Uso de polisacaridos zwitterionicos para la especifica modulacion del progreso inmunologico
|
GB2369896A
(en)
|
2000-12-06 |
2002-06-12 |
Marconi Comm Ltd |
Tunable optical filter actuator
|
KR100442122B1
(ko)
*
|
2001-07-31 |
2004-07-30 |
한국전기연구원 |
영구 자석을 이용한 브러시리스 발전기
|
DE60237170D1
(de)
*
|
2001-12-04 |
2010-09-09 |
Teva Pharma |
Verfahren zur messung der wirkstärke von glatirameracetat
|
ES2322566T3
(es)
*
|
2001-12-06 |
2009-06-23 |
Yeda Research And Development Co., Ltd. |
Vacuna y uso de la misma para el tratamiento de la esclerosis lateral amiotrofica.
|
WO2003059387A2
(en)
*
|
2001-12-21 |
2003-07-24 |
Ilex Oncology, Inc. |
Combination comprising anti-cd52 antibodies and other therapeutic agents for treatment for multiple sclerosis
|
CA2512735C
(en)
|
2003-01-07 |
2016-03-08 |
Yeda Research And Development Co. Ltd. |
Eye-drop vaccine containing copolymer 1 for therapeutic immunization
|
NZ569331A
(en)
*
|
2003-01-21 |
2010-08-27 |
Yeda Res & Dev |
COP 1 for treatment of inflammatory bowel diseases
|
WO2004091573A1
(en)
*
|
2003-03-04 |
2004-10-28 |
Teva Pharmaceutical Industries, Ltd. |
Combination therapy with glatiramer acetate and alphacalcidol for the treatment of multiple sclerosis
|
EP1638581A2
(en)
|
2003-03-31 |
2006-03-29 |
The Brigham And Women's Hospital, Inc. |
Zwitterionic immunomodulators for the treatment of asthma and allergy
|
WO2005041933A1
(en)
*
|
2003-10-31 |
2005-05-12 |
Teva Pharmaceutical Industries, Ltd. |
Nanoparticles for drug delivery
|
EP2301569B1
(en)
|
2003-11-12 |
2018-05-02 |
Yeda Research and Development Co. Ltd. |
Vaccine and method for treatment of neurodegenerative diseases
|
EP1701730B1
(en)
|
2003-12-09 |
2013-08-21 |
Yeda Research And Development Co., Ltd. |
Method and vaccine comprising copolymer 1 for treatment of psychiatric disorders
|
CA2556152A1
(en)
*
|
2004-02-02 |
2005-08-18 |
Mixture Sciences, Inc. |
Peptide mixtures with immunomodulatory activity
|
JP2007527873A
(ja)
*
|
2004-03-01 |
2007-10-04 |
ペプチミューン,インコーポレイテッド |
自己免疫疾患の治療のための方法および組成物
|
EP1778286A4
(en)
*
|
2004-03-03 |
2009-04-08 |
Teva Pharma |
COMBINATION THERAPY WITH ACETATE OF GLATIRAMER AND RILUZOLE
|
US20050260770A1
(en)
*
|
2004-04-01 |
2005-11-24 |
Cohen Irun R |
Antigen array and diagnostic uses thereof
|
WO2005112972A1
(en)
|
2004-05-07 |
2005-12-01 |
Peptimmune, Inc. |
Methods of treating disease with random copolymers
|
US7655221B2
(en)
*
|
2004-05-07 |
2010-02-02 |
Peptimmune, Inc. |
Methods of treating disease with random copolymers
|
US20060194725A1
(en)
*
|
2004-05-07 |
2006-08-31 |
James Rasmussen |
Methods of treating disease with random copolymers
|
SG153871A1
(en)
|
2004-06-25 |
2009-07-29 |
Id Biomedical Corp Quebec |
Compositions and methods for treating neurological disorders
|
PL1797109T3
(pl)
*
|
2004-09-09 |
2016-11-30 |
|
Mieszaniny polipeptydów, kompozycje zawierające je i procesy ich wytwarzania oraz ich zastosowania
|
ZA200702591B
(en)
|
2004-09-09 |
2009-03-25 |
Teva Pharma |
Process for preparation of mixtures of polypeptides using purified hydrobromic acid
|
US8324641B2
(en)
*
|
2007-06-29 |
2012-12-04 |
Ledengin, Inc. |
Matrix material including an embedded dispersion of beads for a light-emitting device
|
WO2006050122A1
(en)
*
|
2004-10-29 |
2006-05-11 |
Sandoz Ag |
Processes for preparing glatiramer
|
WO2006057003A2
(en)
*
|
2004-11-29 |
2006-06-01 |
Yeda Research And Development Co. Ltd. |
Induction of neurogenesis and stem cell therapy in combination with copolymer 1
|
US20060172942A1
(en)
*
|
2005-02-02 |
2006-08-03 |
Teva Pharmaceutical Industries, Ltd. |
Process for producing polypeptide mixtures using hydrogenolysis
|
US20100167983A1
(en)
*
|
2007-10-22 |
2010-07-01 |
Teva Pharmaceutical Industries, Ltd. |
Combination therapy with glatiramer acetate and rasagiline for the treatment of multiple sclerosis
|
SI1848415T1
(sl)
*
|
2005-02-17 |
2013-08-30 |
Teva Pharmaceutical Industries Ltd. |
Kombinacijska terapija z glatiramer acetatom in razagilinom za zdravljenje muliple skleroze
|
WO2006116602A2
(en)
*
|
2005-04-25 |
2006-11-02 |
Yeda Research And Development Company |
Markers associated with the therapeutic efficacy of glatiramer acetate
|
US20070161566A1
(en)
*
|
2006-01-11 |
2007-07-12 |
Teva Pharmaceutical Industries, Ltd. |
Method of treating multiple sclerosis
|
WO2007092451A2
(en)
|
2006-02-06 |
2007-08-16 |
The Brigham And Women's Hospital, Inc. |
Zwitterionic polysaccharides for promotion of immune system maturation and health
|
JP2009536157A
(ja)
|
2006-04-13 |
2009-10-08 |
ペプチミューン,インコーポレイテッド |
エピトープ透過性の指向された拡張を介した指向性配列ポリマー組成物の設計方法および合成方法
|
US8470603B2
(en)
*
|
2006-04-28 |
2013-06-25 |
Momenta Pharmaceuticals, Inc. |
Methods of evaluating diethylamide in glatiramer acetate
|
KR100831796B1
(ko)
*
|
2006-05-29 |
2008-05-28 |
엘지전자 주식회사 |
타임 쉬프트 기능을 내장한 영상표시기기 및 그 재생 방법
|
AU2007264682B2
(en)
|
2006-06-28 |
2012-09-06 |
Yeda Research & Development Co. Ltd |
Method of treatment of age-related macular degeneration
|
DE602007003848D1
(de)
*
|
2006-07-05 |
2010-01-28 |
Momenta Pharmaceuticals Inc |
Verbessertes verfahren zur herstellung von copolymer-1
|
AU2008265692A1
(en)
|
2007-06-21 |
2008-12-24 |
Momenta Pharmaceuticals, Inc. |
Copolymer assay
|
US20090029766A1
(en)
*
|
2007-07-26 |
2009-01-29 |
Lutnick Howard W |
Amusement gaming access and authorization point
|
CA2705046C
(en)
*
|
2007-07-31 |
2015-03-03 |
Natco Pharma Limited |
Process for the preparation glatiramer acetate (copolymer-1)
|
AP3467A
(en)
|
2007-10-16 |
2015-11-30 |
Peptimmune Inc |
Methods for designing and preparing vaccines comprising directed sequence polymer compositions via the directed expansion of epitopes
|
EP2217250A4
(en)
|
2007-11-09 |
2011-01-05 |
California Inst Of Techn |
IMMUNOREGULATORY COMPOUNDS AND RELATED COMPOSITIONS AND METHODS
|
EA201070656A1
(ru)
*
|
2007-11-28 |
2010-12-30 |
Тева Фармасьютикал Индастриз, Лтд. |
Способ задержки начала проявления клинически определенного рассеянного склероза
|
ES2449865T5
(es)
*
|
2008-04-16 |
2022-11-18 |
Momenta Pharmaceuticals Inc |
Análisis de composiciones de copolímeros de aminoácidos
|
EP2307448B1
(en)
*
|
2008-08-07 |
2015-04-22 |
Sigma-Aldrich Co. LLC |
Preparation of low molecular weight polylysine and polyornithine in high yield
|
AU2009279636A1
(en)
*
|
2008-08-07 |
2010-02-11 |
Scinopharm Taiwan, Ltd. |
Synthesis of glatiramer acetate
|
AR074881A1
(es)
|
2008-12-24 |
2011-02-16 |
Synthon Bv |
Un proceso para purificar una mezcla de polimeros
|
EP2414384B2
(en)
*
|
2009-04-03 |
2023-05-03 |
Momenta Pharmaceuticals, Inc. |
Control of copolymer compositions
|
US9150609B2
(en)
|
2009-06-04 |
2015-10-06 |
Council Of Scientific & Industrial Research |
Process for the preparation of copolymer-1 using a polymer supported dialkylamine initiator
|
ATE549013T1
(de)
|
2009-07-15 |
2012-03-15 |
Teva Pharma |
Formulierung von glatirameracetat mit verringertem volumen und verabreichungsverfahren
|
US8920373B2
(en)
|
2009-07-15 |
2014-12-30 |
Teva Pharmaceutical Industries, Ltd. |
Reduced volume formulation of glatiramer acetate and methods of administration
|
US8691790B2
(en)
*
|
2009-07-27 |
2014-04-08 |
James Layne Boucher |
Therapy of neurological inflammatory diseases with (5'-deoxy-5'-adenosyl) cobamamide, recombinant human growth hormone, interleukins IL-1, IL-6, IL-11, epidermal growth factor, and physiotherapy
|
EA032283B1
(ru)
|
2009-08-20 |
2019-05-31 |
Йеда Рисерч Энд Дивелопмент Ко. Лтд. |
Терапия глатирамером ацетатом с низкой кратностью
|
EP2398488B1
(en)
|
2010-01-04 |
2018-11-14 |
Mapi Pharma Limited |
Depot system comprising glatiramer acetate
|
US8377885B2
(en)
|
2010-01-04 |
2013-02-19 |
Mapi Pharma Ltd. |
Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
|
USRE49251E1
(en)
|
2010-01-04 |
2022-10-18 |
Mapi Pharma Ltd. |
Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
|
EP2523668A1
(en)
|
2010-01-13 |
2012-11-21 |
Ramot at Tel-Aviv University Ltd |
Treatment of multiple sclerosis
|
US8759302B2
(en)
*
|
2010-03-16 |
2014-06-24 |
Teva Pharmaceutical Industries, Ltd. |
Methods of treating a subject afflicted with an autoimmune disease using predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis
|
HUE040658T2
(hu)
|
2010-04-07 |
2019-03-28 |
California Inst Of Techn |
Vivõanyag vegyület mukózus membránhoz juttatásához és kapcsolódó készítmények, eljárások és rendszerek
|
NZ603012A
(en)
*
|
2010-04-27 |
2015-01-30 |
Reddy’S Lab Ltd Dr |
Preparation of polypeptides and salts thereof
|
EP2571982A4
(en)
|
2010-05-20 |
2014-01-01 |
California Inst Of Techn |
ANTIGEN-SPECIFIC TREGS AND CORRESPONDING COMPOSITIONS, METHODS AND SYSTEMS
|
KR20130043196A
(ko)
*
|
2010-07-29 |
2013-04-29 |
닥터 레디스 래보러토리즈, 인코포레이티드 |
글라티라머 아세테이트 분자량 마커
|
JP2013541010A
(ja)
|
2010-10-11 |
2013-11-07 |
テバ ファーマシューティカル インダストリーズ リミティド |
グラチラマーアセテートに対する臨床的な反応の予測可能なバイオマーカーとしてのサイトカインバイオマーカー
|
RU2604521C2
(ru)
|
2011-02-14 |
2016-12-10 |
Юсв Прайвит Лимитед |
Сополимер-1, способы его получения и аналитические методы
|
ES2601892T3
(es)
|
2011-04-21 |
2017-02-16 |
Mapi Pharma Limited |
Pentapolímero aleatorio para el tratamiento de enfermedades autoinmunes
|
US20140348861A1
(en)
|
2011-05-05 |
2014-11-27 |
National Institute Of Immunology |
Synthetic peptides and random copolymers for the treatment of autoimmune disorders
|
WO2013009864A1
(en)
|
2011-07-11 |
2013-01-17 |
Momenta Pharmaceuticals, Inc. |
Structure assessment of heterogeneous polypeptide mixtures
|
WO2013009885A2
(en)
|
2011-07-11 |
2013-01-17 |
Momenta Pharmaceuticals, Inc. |
Evaluation of copolymer diethylamide
|
EP2731617A4
(en)
|
2011-07-12 |
2015-07-01 |
Brigham & Womens Hospital |
LIPID-CONTAINING PSA COMPOSITIONS, METHODS OF ISOLATION AND METHODS OF USING SAME
|
US8575198B1
(en)
|
2011-09-07 |
2013-11-05 |
Momenta Pharmaceuticals, Inc. |
In-process control for the manufacture of glatiramer acetate
|
BR112014008752A2
(pt)
|
2011-10-10 |
2017-04-25 |
Teva Pharma |
polimorfismos de nucleotídeos singulares úteis para predizer a resposta clínica para acetato de glatirâmero
|
WO2013139728A1
(en)
|
2012-03-19 |
2013-09-26 |
Synthon Bv |
Glatiramer acetate human monocyte cell-based potency assay
|
EP2642290A1
(en)
|
2012-03-19 |
2013-09-25 |
Synthon BV |
Glatiramer acetate human monocytic cell line-based potency assay
|
US20140045740A1
(en)
*
|
2012-08-13 |
2014-02-13 |
Momenta Pharmaceuticals, Inc. |
Analysis of glatiramer acetate
|
CA2884267A1
(en)
|
2012-10-10 |
2014-04-17 |
Teva Pharmaceutical Industries Ltd. |
Biomarkers predictive for clinical response for glatiramer acetate
|
WO2014060942A2
(en)
*
|
2012-10-20 |
2014-04-24 |
Mahesh Kandula |
Compositions and methods of for the treatment of multiple sclerosis and neurodegenerative diseases
|
WO2014128079A1
(en)
|
2013-02-19 |
2014-08-28 |
Synthon B.V. |
Glatiramer acetate multidose formulation
|
ES2527577T3
(es)
|
2013-03-08 |
2015-01-27 |
Teva Pharmaceutical Industries, Ltd. |
Aparato inyector reutilizable para jeringa
|
RS53779B1
(en)
|
2013-03-08 |
2015-06-30 |
Teva Pharmaceutical Industries Ltd. |
Injectable Reusable Injection Device
|
AU2014244550B2
(en)
|
2013-03-14 |
2018-11-01 |
Mylan Inc. |
Glatiramer acetate response biomarker mRNA potency assay
|
WO2014173463A1
(en)
|
2013-04-26 |
2014-10-30 |
Synthon Bv |
Glatiramer acetate human monocytic cell line-based potency assay
|
CA2911826C
(en)
|
2013-05-10 |
2022-08-23 |
California Institute Of Technology |
Probiotic prevention and treatment of colon cancer
|
CN103265624B
(zh)
*
|
2013-05-27 |
2015-04-22 |
成都圣诺生物制药有限公司 |
格拉替雷的制备方法
|
CN104371012A
(zh)
*
|
2013-08-12 |
2015-02-25 |
深圳翰宇药业股份有限公司 |
一种合成醋酸格拉替雷的方法
|
UY35790A
(es)
|
2013-10-21 |
2015-05-29 |
Teva Pharma |
Marcadores genéticos que predicen la respuesta al acetato de glatiramer
|
CN105917001B
(zh)
|
2013-10-24 |
2020-11-20 |
迈兰公司 |
用于评估醋酸格拉替雷制品的免疫学同一性的人类t细胞系试验
|
JP2017503169A
(ja)
|
2013-12-31 |
2017-01-26 |
イエダ・リサーチ・アンド・デベロツプメント・カンパニー・リミテツド |
オリゴヌクレオチド抗原を使用する全身性エリテマトーデスの診断
|
CA3129892A1
(en)
|
2014-03-12 |
2015-09-17 |
Yeda Research And Development Co. Ltd. |
Reducing systemic regulatory t cell levels or activity for treatment of disease and injury of the cns
|
CN104844697B
(zh)
|
2014-09-26 |
2018-10-23 |
深圳翰宇药业股份有限公司 |
醋酸格拉替雷的制备方法
|
US9155775B1
(en)
|
2015-01-28 |
2015-10-13 |
Teva Pharmaceutical Industries, Ltd. |
Process for manufacturing glatiramer acetate product
|
CN107533058A
(zh)
|
2015-03-01 |
2018-01-02 |
免疫阵列有限公司 |
使用蛋白、肽和寡核苷酸抗原诊断系统性红斑狼疮
|
US11331335B2
(en)
|
2015-06-10 |
2022-05-17 |
California Institute Of Technology |
Sepsis treatment and related compositions methods and systems
|
US10857177B2
(en)
|
2015-08-19 |
2020-12-08 |
President And Fellows Of Harvard College |
Lipidated PSA compositions and methods
|
EP3147667B1
(en)
|
2015-09-24 |
2019-06-12 |
CHEMI S.p.A. |
Analysis of the molecular weight distribution of complex polypeptide mixtures
|
EP3170836B1
(en)
|
2015-11-23 |
2018-10-24 |
Chemi SPA |
Rp-hplc analysis of complex polypeptide mixtures
|
CN107522774B
(zh)
*
|
2016-06-22 |
2021-07-02 |
深圳翰宇药业股份有限公司 |
一种醋酸格拉替雷制备过程中哌啶残留量的实时控制方法
|
WO2018002930A1
(en)
|
2016-06-30 |
2018-01-04 |
Stem Cell Medicine Ltd. |
Treatment of inflammatory bowel disease with long acting glatiramer and adipose-derived stem cells
|
EP3484441A4
(en)
|
2016-07-15 |
2020-03-18 |
President and Fellows of Harvard College |
GLYCOLIPID COMPOSITIONS AND METHODS OF USE
|
MX2019001999A
(es)
|
2016-08-28 |
2019-08-29 |
Mapi Pharma Ltd |
Proceso para la preparacion de microparticulas que contienen acetato de glatiramer.
|
DK3506921T3
(da)
|
2016-08-31 |
2023-07-31 |
Mapi Pharma Ltd |
Depotsystemer, der omfatter glatirameracetat
|
BR112019017724A2
(pt)
|
2017-03-26 |
2020-03-31 |
Mapi Pharma Ltd. |
Sistemas depot de glatiramer para tratar formas progressivas de esclerose múltipla
|
WO2018211498A1
(en)
|
2017-05-15 |
2018-11-22 |
Stem Cell Medicine Ltd. |
Treatment of multiple sclerosis with adipose-derived stem cells
|
EP3624815A4
(en)
|
2017-05-15 |
2021-01-20 |
Stem Cell Medicine Ltd. |
TREATMENT OF MULTIPLE SCLEROSIS WITH LONG-ACTING GLATIRAMER AND ADAPTIVE STEM CELLS
|
WO2019175869A1
(en)
|
2018-03-12 |
2019-09-19 |
Yeda Research And Development Co. Ltd |
Treatment of a heart disease
|